Answers are grounded in this paper and cite their sources.
High Mobility Group AT-hook 2 (HMGA2), a recognized oncogene in myeloproliferative neoplasm (MPN), is regulated by dozens of microRNAs (miRNAs), notably, let-7a. We hypothesize that other miRNAs might influence HMGA2-associated phenotypic characteristics in MPN, as well. To explore further, we applied a miRNA library screening system to identify potential HMGA2 mRNA 3′-untranslated region (3′UTR)-targeting candidates and evaluated their functional effects in MPN cell models. MicroRNA-93 (miR-93) was among the few HMGA2 3′UTR-targeting miRNAs differentially expressed in MPN cells, being downregulated in CALR-mutated cells but not in JAK2V617F-mutated cells. Correspondingly, HMGA2 overexpression was observed in CALR-mutated cells. Luciferase reporter assays confirmed that miR-93 could target a highly conserved sequence within the HMGA2 3′UTR region. Upregulation of miR-93 in CALR-mutated cells significantly impeded cellular growth and increased apoptosis in vitro. Rapid development of myelofibrosis phenotypes was observed in immune-deficient mice transplanted with CALR-mutated cells. Ectopic expression of miR-93 in these cells attenuated myelofibrosis-like phenotypes in vivo and prolonged the survival of these mice. Clinically, higher miR-93 expression was associated with features suggesting a more indolent disease course in a small cohort of CALR-mutated MPN patients, although these observations were exploratory. Collectively, our experimental findings support a potential tumor-suppressive role for miR-93 in CALR-mutated MPN, while the clinical associations require further validation in larger patient cohorts.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: